<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04824404</url>
  </required_header>
  <id_info>
    <org_study_id>87691</org_study_id>
    <nct_id>NCT04824404</nct_id>
  </id_info>
  <brief_title>CBT4CBT-Buprenorphine + Recovery Coach for Office-based Buprenorphine</brief_title>
  <official_title>Integrated Intervention Combining CBT4CBT-Buprenorphine + Recovery Coach for Office-based Buprenorphine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prisma Health-Upstate</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clemson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Prisma Health-Upstate</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To conduct an 8-week pilot, randomized trial evaluating the feasibility, acceptability, and&#xD;
      efficacy of an integrated intervention involving CBT4CBT-Buprenorphine + Recovery Coach in a&#xD;
      population of 60 individuals who meet current DSM criteria for opioid use disorder and are&#xD;
      receiving buprenorphine treatment in primary care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this pilot study, 50 individuals with OUD on buprenorphine will be randomized to either 1)&#xD;
      standard of care (N=25) or (2)CBT4CBT-Buprenorphine + Recovery Coach (N=250). This will be an&#xD;
      8-week trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">May 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in drug use</measure>
    <time_frame>0-8 weeks</time_frame>
    <description>Using saliva toxicology tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention to buprenorphine</measure>
    <time_frame>3 month follow up</time_frame>
    <description>enrollment in and receiving buprenorphine and/or other effective medication treatment for OUD which will be verified by either report from the treatment clinic or electronic medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in drug use</measure>
    <time_frame>1 and 3 month follow up</time_frame>
    <description>Using saliva toxicology tests</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Commission errors</measure>
    <time_frame>0-8 weeks</time_frame>
    <description>This score indicates the number of times e client responded but no target was presented. A fast reaction time and high commission error rate points to difficulties with impulsivity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Selective attention</measure>
    <time_frame>0-8 weeks</time_frame>
    <description>This outcome will be measured by the Stroop Color and Word Test. This Stroop Test has three parts that generate simple and complex reaction times. Averaging the two complex reaction time scores from the Stroop Test generates a domain score for &quot;reaction time.&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive performance through Electroencephalogram</measure>
    <time_frame>0-8 weeks</time_frame>
    <description>This outcome will be measured by alpha, the dominant frequency in the human scalp EEG of adults.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>Standard Treatment As Usual (TAU)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly or bi-weekly visits (at the discretion of the provider) to the clinic to meet with their provider and provide a sample of blood.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBT4CBT-Buprenorphine + Recovery Coach</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This condition will consist of the CBT4CBT-Buprenorphine intervention alongside weekly coaching sessions from a recovery professional</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT4CBT-Buprenorphine + Recovery Coach</intervention_name>
    <description>This condition will consist of the CBT4CBT-Buprenorphine intervention alongside weekly coaching sessions from a recovery professionalCBT4CBT-Buprenorphine is an 8-session (module) system for teaching a wide range of CBT skills (understanding and changing patterns of substance use; coping with craving; refusing offers of drugs and alcohol; problem-solving skills; identifying and changing thoughts about drugs and alcohol; and improving decision-making skills)</description>
    <arm_group_label>CBT4CBT-Buprenorphine + Recovery Coach</arm_group_label>
    <other_name>CBT4CBT+ Recovery Coach</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults (â‰¥18 years)&#xD;
&#xD;
          -  having a DSM-V diagnosis of OUD&#xD;
&#xD;
          -  sublingual buprenorphine/naloxone and/or buprenorphine&#xD;
&#xD;
          -  having initiated maintenance treatment for OUD for at least 30 days before the&#xD;
             screening&#xD;
&#xD;
          -  self-report or toxicology screening positive for any substance within 30 days of&#xD;
             screening;&#xD;
&#xD;
          -  willing to accept a random assignment to either TAU/CBT4CBT-Buprenorphine + Recovery&#xD;
             Coach;&#xD;
&#xD;
          -  having adequate computer skills&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  having a severe medical or psychiatric disability that could impair their ability to&#xD;
             perform study-related activities (determined by the clinician)&#xD;
&#xD;
          -  being pregnant or breastfeeding;&#xD;
&#xD;
          -  being unable to independently read and/or comprehend the consent form or other study&#xD;
             materials&#xD;
&#xD;
          -  being unable to read/speak English;&#xD;
&#xD;
          -  having current suicidal ideation based on the Patient Health Questionnaire-9.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alain Litwin, MD</last_name>
    <phone>8644556658</phone>
    <email>alain.litwin@prismahealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irene Pericot-Valverde, PhD</last_name>
    <phone>8549998005</phone>
    <email>iperico@clemson.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Internal Medicine Recovery Clinic</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Mavis</last_name>
      <phone>864-455-8929</phone>
      <email>Jessica.Mavis@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Alain H Litwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irene Pericot-Valverde, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angelica Perez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moonseong Heo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

